» Articles » PMID: 20487223

Gastroprotective Activity of Atractylenolide III from Atractylodes Ovata on Ethanol-induced Gastric Ulcer in Vitro and in Vivo

Overview
Specialties Pharmacology
Pharmacy
Date 2010 May 22
PMID 20487223
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The rhizome of Atractylodes ovata De Candolle is popularly used in traditional Chinese medicine to treat gastrointestinal diseases. However, the major gastroprotective compounds of A. ovata have not been identified. This study reports on the principal gastro- protective component of A. ovata.

Methods: Five sesquiterpenoids (atractylon, atractylenolides I, II, III and biatractylolide) were isolated from the extracts of A. ovata rhizome via silica gel column chromatography. The gastroprotective effects of these five sesquiterpenoids were measured in in-vitro ethanol-induced primary culture rat gastric mucosal (PRGM) cell damage and in-vivo ethanol-induced acute rat gastric ulcer models.

Key Findings: Atractylon, atractylenolide I and biatractylolide were strongly toxic in PRGM cells, whilst atractylenolides II and III were not. Atractylenolide II did not show cytoprotective effects, but oral administration of atractylenolide III dose-dependently prevented ethanol-induced PRGM cell death and cell membrane damage. The EC50 values were 0.27 and 0.34 mm, respectively. In the in-vivo assay, atractylenolide III 10 mg/kg significantly reduced 70% ethanol-induced Wistar rat gastric ulcer. Atractylenolide III could inhibit matrix metalloproteinase (MMP)-2 and MMP-9 expression through upregulation of tissue inhibitors of metalloproteinase from the gastric ulcerated tissues.

Conclusions: Atractylenolide III was the major gastroprotective component of A. ovata in ethanol-induced acute gastric ulcer. It is suggested that the gastroprotective mechanism of atractylenolide III was via inhibition of the MMP-2 and MMP-9 pathway.

Citing Articles

Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.

Liao W, Wang J, Li Y J Pharm Anal. 2025; 15(2):101075.

PMID: 39957902 PMC: 11830317. DOI: 10.1016/j.jpha.2024.101075.


Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy.

Qian H, Ye Z, Hu Y, Wu M, Chen L, Li L Front Pharmacol. 2024; 15:1398294.

PMID: 38860174 PMC: 11163078. DOI: 10.3389/fphar.2024.1398294.


Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway.

Lin Y, Chen K, Zhu M, Song W, Wu G, Pan A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7697-7710.

PMID: 38709266 DOI: 10.1007/s00210-024-03046-2.


Phytochemistry and Pharmacology of Sesquiterpenoids from DC. Genus Rhizomes.

Qu Z, Liu H, Zhang Z, Zheng P, Zhao S, Hou W Molecules. 2024; 29(6).

PMID: 38543015 PMC: 10975564. DOI: 10.3390/molecules29061379.


Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review.

Xie Z, Lin M, He X, Dong Y, Chen Y, Li B Molecules. 2023; 28(10).

PMID: 37241729 PMC: 10224166. DOI: 10.3390/molecules28103987.